• Contact us
  • E-Submission

Ewha Med J : The Ewha Medical Journal

OPEN ACCESS
mobile search button mobile menu button
Search
Advanced Search
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Articles

Page Path

Review Article

The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer

Hyun-Ah Kim, Joohyun Woo1, Hyang Suk Choi, Seok Joon Lee, Jihye Choi, Chan Sub Park, Min-Ki Seong, Woo Chul Noh
The Ewha Medical Journal 2017;40(3):104-107. Published online: July 28, 2017

Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Seoul, Korea.

1Department of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.

Corresponding author: Hyun-Ah Kim. Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. Tel: 82-2-970-1280, Fax: 82-2-970-2419, hyunah@kcch.re.kr
• Received: May 17, 2017   • Revised: May 22, 2017   • Accepted: May 23, 2017

Copyright © 2017. Ewha Womans University School of Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 36 Views
  • 0 Download
next

Full Article

Download PDF Download PDF
  • The evaluation of menopausal status is an important subject in the field of treatment of hormone receptor positive breast cancer. According to the menopausal status, endocrine therapy should be categorized by individual patient. However, the gonadal injury caused by various therapeutic drugs and its recovery would confuse the interpretation of clinical and biological markers for ovarian reserve. There are some methods to examine the functional ovarian reserve indirectly. Ultrasonography for counting follicles is a relatively reliable procedure, although it is not feasible because of time-labor consumption and high cost. Biological marker from blood samples such as serum follicle stimulating hormone (FSH), serum estradiol (E2), serum inhibin, or anti-Müllerian hormone (AMH) would be a better choice. The examination of serum FSH and E2 is already recommended as biomarkers for measuring functional ovarian reserve in many guidelines. However, there are limitation of serum FSH and E2 in patients with chemotherapy-induced amenorrhea and treated by tamoxifen. AMH is promising biomarker in the field of infertility treatment even in the patients treated by chemotherapy. It might be a possible biomarker to determine the menopausal status for decision-making whether aromatase inhibitor could be applicable or not in hormone positive breast cancer patients with chemotherapy induced amenorrhea or treated by tamoxifen.
  • Keywords: Breast neoplasms; Anti-Mullerian hormone; Premenopause; Receptors; Estrogen
  • 1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method for treatment with illustrative cases. Lancet 1896;148:162-165.
  • 2. Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart M. Endocrine treatment in breast cancer: Cure, resistance and beyond. Cancer Treat Rev 2016;50:68-81.
  • 3. Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, et al. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol 2016;34:1594-1600.
  • 4. Park EH, Min SY, Kim Z, Yoon CS, Jung KW, Nam SJ, et al. Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer 2017;20:1-11.
  • 5. National Comprehensive Cancer Network (NCCN)NCCN Guidelines [Internet] Fort Washington, PA, NCCN. c2017;cited 2017 Jul 4. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
  • 6. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered. Lancet Oncol 2005;6:209-218.
  • 7. Ben-Haroush A, Farhi J, Zahalka Y, Sapir O, Meizner I, Fisch B. Correlations between antral follicle count and ultrasonographic ovarian parameters and clinical variables and outcomes in IVF cycles. Gynecol Endocrinol 2012;28:432-435.
  • 8. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 2012;8:331-341.
  • 9. Meczekalski B, Czyzyk A, Kunicki M, Podfigurna-Stopa A, Plociennik L, Jakiel G, et al. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. J Endocrinol Invest 2016;39:1259-1265.
  • 10. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21:3103-3107.
  • 11. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 2009;7:100.
  • 12. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013;137:571-577.
  • 13. Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer 2014;21:R51-R65.
  • 14. Anderson RA, Cameron DA. Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336-1343.
  • 15. Kim HA, Seong MK, Kim JH, Kim YG, Choi HS, Kim JS, et al. Prognostic value of anti-Müllerian hormone and inhibin B in patients with premenopausal hormone receptor-positive breast cancer. Anticancer Res 2016;36:1051-1057.
  • 16. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010;116:592-599.

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Download Citation

      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:

      Include:

      The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer
      Ewha Med J. 2017;40(3):104-107.   Published online July 28, 2017
      DOI: https://doi.org/10.12771/emj.2017.40.3.104
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer
      Ewha Med J. 2017;40(3):104-107.   Published online July 28, 2017
      DOI: https://doi.org/10.12771/emj.2017.40.3.104
      Close
      The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer
      The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer
      Ewha Med J : The Ewha Medical Journal

      ABOUT

      BROWSE ARTICLES 

      JOURNAL POLICIES

      FOR CONTRIBUTORS 

      © Ewha Womans University College of Medicine.
      TOP